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Abstract  
Introduction: Weight loss (WL) is a frequent yet under-recognized complication of 
levodopa/carbidopa intestinal gel (LCIG) infusion, as well as a milestone of Parkinson 
disease (PD) disability progression. The complex association between weight loss, poor 
nutritional status, motor complications, and PD progression, however, remains unclear.  
Methods: Consecutively consenting PD patients treated with LCIG (n= 44; PD duration= 
18.3±6.5 years) were enrolled in an open-label observational study assessing the extent of 
WL occurring during LCIG treatment. As secondary aims, we correlated the nutritional 
status, as detected by the mini nutritional assessment (MNA), with the severity of motor 
symptoms (Movement Disorders Society Unified Parkinson’s Disease Rating Scale (MDS-
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UPDRS) section-III), motor complications (UPDRS section-IV), activities of daily living 
(Schwab  England scale), cognitive impairment (Mini Mental State Examination - MMSE), 
depression (Beck Depression Inventory - BDI), difficulties in feeding (Edinburgh feeding 
evaluation in dementia questionnaire - EdFED-Q), and levodopa equivalent daily dose 
(LEDD). 
Results: There was an average WL of 9.9±10.5% (7.6±7.1 kg) over an LCIG treatment 
period of 51.6±28.5 months. The extent of WL correlated with the percentage of waking day 
spent with dyskinesia (p< 0.05). The nutritional status correlated with motor symptoms 
severity (p< 0.01), dysphagia (p< 0.01), and LEDD (p< 0.01).  
Conclusion: WL may occur in PD patients undergoing LCIG in correlation with the 
percentage of the waking day spent with dyskinesia. Regardless of the extent of WL, the 
nutritional status correlated with higher LEDD, as well as with indexes of disease 
progression, such as motor symptoms severity and dysphagia.  
 
Introduction 
Patients with Parkinson’s disease (PD) are consistently reported to be underweight compared 
to healthy subjects [1]. Weight loss (WL) may begin several years prior to the clinical 
diagnosis [2] in association with various factors, including PD-associated hyposmia, 
dysphagia, difficulties in self-feeding, intestinal hypomotility, depression, cognitive 
impairment, anorexia, and nausea, as well as with increased energy expenditure due to 
rigidity, tremor, and levodopa-induced dyskinesia [1, 3].  
Multiple evidences suggest a key role for WL as a biomarker of disease progression in PD 
and other neurodegenerative disorders [4, 5]. In fact, the body mass index (BMI), which is 
calculated as weight in kilograms divided by height in square meters, is a strong predictor of 
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survival in PD [4, 5]. Moreover, WL correlates with several non-motor complications directly 
associated with poor PD functional status, such as cognitive impairment and orthostatic 
hypotension [3].  
In previous studies, we found that PD patients treated with levodopa/carbidopa intestinal gel 
(LCIG) infusion may be particularly susceptible to WL. Causative factors for this 
phenomenon, however, remain partially unclear and are likely related to a multifactorial 
interplay between intestinal malabsorption, global deterioration of the overall clinical 
conditions, and a possible effect of dopaminergic medications on the appetite [6, 7].  
The main aim of this study is to evaluate prevalence and severity of WL occurring during 
LCIG treatment and to analyze the association between the nutritional status of PD patients 
undergoing LCIG and motor and non-motor indexes of PD disability progression.  
 
Patients and Methods 
Inclusion criteria were idiopathic PD, as per the UK Brain Bank criteria [8]; treatment with 
LCIG for at least 6 months; and availability of weight measurement before starting LCIG. 
Exclusion criteria were signs or symptoms suggestive of atypical parkinsonism; bariatric 
surgery; poor general health; and medical conditions potentially associated with pathological 
WL such as gastroenteric disorders, malignancies, thyroid dysfunction, etc.  
As primary endpoints, we measured changes in the body weight and BMI between T0 (about 
one week, range: 1-7 days, before starting LCIG) and T1 (last outpatient visit  on LCIG 
therapy). Secondary endpoints included the Mini Nutritional Assessment (MNA), an 18-item 
questionnaire based on anthropometric measurements, eating habits, psychological, and 
functional aspects associated with nutrition specifically validated for nutritional assessment 
of community and institutionalized elderly patients [9]; the Edinburgh Feeding Evaluation in 
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Dementia Questionnaire (EdFED-Q), a 11-items clinical questionnaire assessing behaviours 
of feeding difficulty (e.g. refusing to eat, turning head away while being fed, spitting out 
food), nursing intervention (e.g. supervision, physical help) and patient passivity during 
meals (e.g. spillage, leftover) [10]; the Movement Disorders Society Unified Parkinson’s 
Disease Rating Scale (MDS-UPDRS) part-II, part-III, and UPDRS part-IV; the Mini Mental 
State Examination (MMSE); the Beck Depression Inventory Scale (BDI); the Schwab and 
England (SE) scale of activities of daily living (ADL); and the levodopa equivalent daily dose 
(LEDD), calculated as per a validated conversion table [11] and expressed as LEDD/Kg. 
Items 32 and 33 of the UPDRS were used to assess the duration and severity of dyskinesia, 
the MDS-UPDRS item 2.3 to rate the severity of dysphagia. Validated conversion tables were 
applied to convert data from the UPDRS part-II and -III to the MDS-UPDRS part-II and -III, 
when needed [12]. 
All patients were evaluated for peripheral neuropathy (PNP), defined as symmetric alteration 
of action potential amplitudes or velocities in at least two motor or sensory nerves at the 
nerve conduction studies (NCS) [13]. PNP were classified as “subclinical” when presenting 
with electrophysiological alteration not accompanied by clinical symptoms.  
The ethical committee approval was obtained (CS2/535; protocol number 0006409) and 
patients provided written informed consent. 
 
Statistical analysis 
Continuous variables were described as mean ± standard deviation. Categorical variables as 
frequencies or percentage. Changes in body weight between T0 and T1 were calculated as per 
the following formula: (∆ kg [T0-T1]/body weight at T0)*100). Correlations analyses were 
carried out using a two-step approach. First, a Pearson’s rank correlation coefficient was 
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applied. Then, data showing significant correlation at the univariate analysis were selected as 
independent variables in a multiple linear regression model adjusting for PD duration and 
LCIG treatment duration. Two-tailed p-values lower than 0.05 were considered statistically 
significant. Analyses were carried out using SPSS 24.0 (SPSS, Chicago, IL). 
 
Results 
We enrolled 44 patients, corresponding to 82% of the entire population (n = 54) in active 
treatment with LCIG at our center. Exclusions were due to poor general health (n = 3 cases), 
LCIG duration shorter than 6 months (n = 3 cases), lack of data at T0 (n= 2 cases), 
detainment in prison (n = 1 case), and diagnostic revision into multiple system atrophy (n = 1 
case). The duration of LCIG therapy was 51.6 ± 28.5 months (range: 10-120 months). 
Clinical, demographic, and nutritional data are detailed in Table 1.  
There was an average WL of 9.9 ± 10.5% between T0 and T1, corresponding to a weight 
change greater than 10 Kg in 12 patients (27%); ranging from 6 to 10 Kg in 12 patients 
(27%); and from 2 to 5 Kg in 6 patients (13%). No significant weight changes were observed 
in the remaining 16 patients.  
At T1, 19 patients (43%) had a BMI < 22 kg/m
2
, which is considered the threshold for 
undernutrition in elderly population; 9 (21%) met the criteria for malnutrition (MNA score < 
17) and 6 (14%) required nocturnal enteral feeding to supplement their dietary intake. 
Motor complications (UPDRS-IV) improved due to a reduction in the severity of wearing-
off, while no significant changes were observed in the duration and severity of dyskinesia 
(Table 1). The prevalence of PNP increased between T0 and T1, with 8 cases of subclinical 
PNP becoming “symptomatic”, and 8 cases with normal neurophysiological examination 
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developing a subclinical PNP (p=0.001; Table 1). The dose of dopaminergic therapies 
significantly increased between T0 and T1 (p=0.002). 
A direct correlation was observed between the extent of WL and the percentage of waking 
day spent with dyskinesia (β=0.381; p =0.006), and between MNA and the following 
variables: HY score (β=0.287; p =0.012); dysphagia severity (β=0.227; p =0.007); MDS-
UPDRS-III total score at T1(β=0.320; p =0.009); EdFED-Q total score (β=0.320; p =0.008); 
and LEDD/Kg (β=0.290; p =0.002) (Table 2). Patients developing clinical or subclinical PNP 
between T0 and T1 showed a worse nutritional status (p=0.005) though not a greater WL. 
 
Discussion 
The complex relationship between food intake and weight changes in PD remains unclear. 
Regardless of food intake, PD patients have lower BMI than healthy subjects [14]. Moreover, 
a decrease in the BMI correlates with a more aggressive pattern of motor symptoms 
progression [4], suggesting that PD-associated body weight changes are not necessarily due 
to reduced caloric intake but may rather correlate with underlying disease mechanisms. 
The relationship between WL and PD is even more complex in patients undergoing LCIG. In 
a previous study, we found that 17% of patients treated with LCIG developed a WL greater 
than 10kg over a 2-year observational period [6]. Significant changes in body weight were 
also reported by other authors. Sensi and colleagues described an average WL of 14.7% (10.8 
kg) over a 6-year follow-up in patients treated with LCIG, Antonini and colleagues reported a 
WL of 6.7% over 24 months, and Buongiorno and colleagues a WL of 7% over 22 months [6, 
15-17].  
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To the best of our knowledge, this is the first study specifically investigating factors 
associated with body weight changes in PD patients with long-term exposure to LCIG. We 
found that 68% of patients developed a mild to severe WL after 4.5 ± 2.3 years, 27% had a 
WL greater than 10kg, and 21% met the criteria for malnutrition. After adjusting for LCIG 
duration, the duration of dyskinesia was the only factor associated with WL, while severity of 
motor symptoms, dysphagia, and dose of dopaminergic medications correlated with the 
nutritional status.  
Overall, we observed a prevalence and severity of WL that was relatively higher compared to 
other studies [7, 16, 17], possibly reflecting the greater level of attention devoted to body 
weight, an outcome frequently neglected or relegated to the role of ancillary measure. 
However, we cannot exclude the influence of factors such as the long follow-up duration and 
the inclusion of patients in an advanced stage of disease. Interestingly, we did not find any 
correlations between WL and disease severity, expressed as motor disability (i.e. SE, HY, 
MDS-UPDRS-III or ∆MDS-UPDRS-III), cognitive or neuropsychological impairment 
(MMSE, BDI and MDS-UPDRS items 1.1-1.5), and peripheral nervous system involvement. 
Instead, we observed an association between WL and the percentage of the waking day spent 
with dyskinesia. A post-hoc analysis of our data suggests that an adjustment in the dose of 
dopaminergic therapies for body weight changes might be required to minimize dyskinesia 
due to a relative LEDD/kg increase, which may ultimately worsen the severity of peak-dose 
dyskinesia with increased energy expenditure and consequent WL [3, 18]. Also, the relatively 
low score observed at the EdFED-Q indicates that WL was primarily due to increased energy 
expenditure rather than feeding difficulties.  
Since WL not necessarily implies malnutrition [19], we used the MNA to investigate factors 
primarily contributing to the nutritional status. Overall, we observed that 43% of patients 
were at risk of malnutrition and 21% were undernourished. These data are in line with the 
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published literature, which reports a 0 to 24% prevalence of malnutrition in PD, depending on 
the study methodology and definition criteria [20]. Interestingly, we found that dyskinesia 
alone is not a determinant of nutritional status, while disease severity (expressed as HY 
staging and MDS-UPDRS-III score), dysphagia, feeding difficulties (expressed as EdFED-Q 
score), dosage of dopaminergic therapies (expressed as LEDD/Kg) and the developing or 
worsening of a preexisting PNP, correlate with the nutritional state. These data confirm the 
association between late-stage PD and malnutrition [20]. Of relevance, six of our patients 
successfully used the PEG-J tube to supplement their daily food intake with nocturnal enteral 
feeding. Additionally, in spite of the symptomatic LCIG effect on off-time reduction, our data 
indicate that this device-aided treatment seems to have no beneficial effect on the underlying 
neurodegenerative disease effect of PD, at least regarding two possible markers of disease 
progression such as WL and malnutrition. However, this speculation should be confirmed by 
a case-control study. Finally, an effect of LCIG on the intestinal flora and production of gut 
hormones affecting hunger cannot be excluded. Small intestinal bacterial overgrowth (SIBO) 
have been reported to be more common among PD patients if compared to controls [21]. 
SIBO has been associated to a severe pattern of PD symptoms, motor complications and axial 
disability, as well as to a possible malabsorption of dopaminergic medications [22].  While 
the interaction between LCIG and SIBO has not been investigated yet, specific studies seem 
required when considering the possible susceptibility to changes in the microbiota 
composition of patients receiving a therapy delivered though a feeding tube and the high 
frequency of gastrointestinal symptoms observed in association with LICG.  
In sum, our data highlight the importance of devoting specific attention, as well as periodic 
nutritional assessments in patients undergoing LCIG. The assessment of PD patients 
developing WL should include the evaluation of different possible causes, not only related to 
dyskinesias or motor complications, but also to dysphagia, cognitive impairment, 
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hallucinations, apathy, depression, and self-feeding difficulties, which should always be 
considered in advanced PD. The possibility of nocturnal enteral feeding should also be 
contemplated as an effective option in LCIG-treated PD patients, since a feeding tube is 
already available [23]. 
Several limitations should temper the strength of our conclusions, including the retrospective 
analysis of data collected as part of an open label observational study, and the lack of a 
control group treated with oral levodopa. Our main aim, however, was to investigate the 
prevalence and severity of WL in patients undergoing LCIG treatment rather than comparing 
LCIG and oral levodopa treatments.  
 
Conclusions 
Weigh loss may occur in over 60% of PD patients undergoing LCIG. Special attention is 
required in patients with dyskinesia, which might account for an increased energy 
expenditure. Clinicians should also consider that nutritional status of PD patients is 
independently related to indexes of disease progression such as motor symptoms severity and 
dysphagia. Periodic nutritional assessments seem required to identify patients that could 
benefit from additional enteral feeding. In addition, a reduction in the LCIG dose might be 
required to adjust for changes in the LEDD/kg ratio in patients developing WL.  
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LEGEND FOR TABLES 
Table 1. Demographic, clinical and nutritional data of PD patients in treatment with 
LCIG. 
 Baseline 
 (n=44) 
Follow-up 
 (n=44) 
P - value 
Age (yrs) 67.4 ± 5.8 71.7 ± 6.6 / 
Women (n/total (%)) 15/44 (34%) / / 
Age at disease onset (yrs) 53 ± 7.8 / / 
Disease duration (yrs) 14 ± 5.8 18.3 ± 6.5 <0.001 
Duodopa therapy duration (months) / 51.6 ± 28.5 / 
LEDD 
LEDD/Kg 
1421 ± 335 
20.5 ± 6 
1533 ± 474 
24.6 ± 8.4 
0.069 
0.002 
Clinical Phenotype n (%) AK= 34 (77%) 
TD= 10 (23%) 
/ 
/ 
 
HY 
Number per stage 
 
3 ± 0.9 
2= 18; 3=5;  
4=21 
3.3 ±1.2 
2= 17; 3= 4; 4= 14;  
5= 9; 
0.003 
SE 63±  13 56 ± 19 <0.001 
MDS.UPDRS II 17.1 ±.7.2 29.5 ± 9.6 <0.001 
MDS.UPDRS III 31±12.4 49.2 ±15 <0.001 
UPDRS IV, Total score (items 32–42) 
Dyskinesia duration (Item 32) 
Dyskinesia disability (Item 33) 
Off state duration (Item 39) 
9.5 ± 3.1 
1.7 ± 1 
1.2 ± 1.2 
2 ± 0.6 
6.1 ± 2.4  
1.7 ± 0.8 
1.2 ± 0.8 
0.8 ± 0.5 
<0.001 
0.7 
0.9 
<0.001 
MMSE 27.2 ± 2.4 24.1 ±4^ <0.001 
BDI 14.5 ± 7.8 18.5 ±9.5^ 0.01 
WL (kg) – n (%) 
% WL (∆WL/weight at T0) 
/ 
/ 
7.6 ± 7.1 – 30 (68%) 
9.9 ± 10.5 
/ 
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WL ≥ 10kg, n (%) / 12 (27%) 
BMI (Kg/m
2
) 
BMI < 22 kg/m
2
, n (%) 
26.1 ± 4.6 
7 (16%) 
23.1 ± 4.1 
19 (43%) 
<0.001 
MNA total score 
MNA classification, n (%) 
NA 
NA 
20.6 ± 4.5 
Normal nutrition status: 16 (36%) 
Undernutrition risk: 19 (43%) 
Undernutrition state: 9 (21%) 
/ 
EdFED-Q / 2.3 ± 3.1   
Excessive granulation tissue, n (%) 
Device related complications (tube 
occlusion or stoma infection), n (%) 
/ 18 (40%) 
 
17 (39%) 
/ 
 
/ 
PNP (Total), n (%) 
Subclinical PNP, n (%) 
Clinical PNP, n (%) 
9 (20%) 
8 (18%) 
1 (2%) 
17 (38%) 
8 (18%) 
9 (20%) 
<0.001 
Nutrition consultancy, n (%)* 
Replacement therapy (Vitamin B12 
and Folic acid) 
Oral nutritional supplement, n (%) 
Enteral feeding, n (%) 
000 
0 
0 
17 (38%) 
17 (38%) 
 
9 (20%) 
6 (14%) 
/ 
/ 
 
/ 
/ 
 
Values are presented as mean ± standard deviation (SD) if not otherwise specified. SE: 
Schwab and England ADL Scale; HY: Hoehn Yahr Stage; LEDD: Levodopa equivalent daily 
dose; MMSE: Mini Mental State Examination; BDI: Beck Depression Inventory Scale; 
MNA: Mini nutritional assessment (total score <17 indicates undernutrition and 17-23.5 
undernutrition risk, while over 24 is considered a normal nutritional status); BMI: body max 
index; EdFED-Q: Edinburgh Feeding Evaluation in Dementia Questionnaire; PNP: peripheral 
polyneuropathy; (*): at least one nutrition consultancy since LCIG treatment onset; (^): one 
patient did not succeeded in filling out the MMSE and BDI a T1 due to a severe dementia. 
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Table 2. Univariate analysis and multiple linear regression analysis for weight loss and 
nutritional status 
 Univariate analysis 
 % of Weight loss* 
 R P - value 
∆LEDD/Kg  0.479 0.01 
LEDD/Kg  0.336 0.02 
UPDRS part IV 0.481 0.001 
“Dyskinesia duration”(item 32)  0.563 0.001 
“Off-state duration” (item 39) 0.40 0.007 
MNA score  0.408 0.006 
 Multiple linear regression analysis 
Co-variable β P - value 
 
“Dyskinesia duration” (item 32) 0.408 0.033 
 Univariate analysis 
 MNA score^^ 
R P-value 
HY  0.663 <0.01 
SE 0.575 <0.01 
MDS-UPDRS-III  0.527 <0.001 
UPDRS-IV 0.4 0.07 
“off-state duration”(item 39) -0.318 0.035 
Dysphagia severity (MDS-UPDRS 
item 2.3) 
-0.482 0.001 
Cognitive/mood profile (MDS-
UPDRS items 1.1-1.5) 
-419 0.005 
EdFED-Q -0.684 <0.001 
MMSE  0.499 <0.001 
LEDD/Kg  -0.398 0.07 
∆WL  -0.315 0.015 
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 Multiple linear regression analysis 
Co-variables β P - value 
 
HY 0.308 0.014 
Dysphagia severity (MDS-UPDRS 
item 2.3) 
0.236 0.012 
MDS-UPDRS-III 0.348 0.015 
EdFED-Q 0.331 0.017 
LEDD/Kg 
 
 
0.309 0.002 
 
 (*) At the univariate analysis, no correlations were found with age, gender, clinical 
phenotype, disease duration, MMSE, BDI, LCIG treatment duration, dysphagia severity 
(MDS-UPDRS item 2.3), cognitive/mood profile (sum of the MDS-UPDRS items 1.1- 1.2- 
1.3 -1.4-1.5), constipation severity (MDS.UPDRS item 1.11), “dyskinesia disability” (item 
33), SE, HY, MDS-UPDRS-III, ∆MDS-UPDRS-III, MMSE, the use of enteral feeding and 
the occurrence of device related complications. (^^) In addition, no correlations were found 
with age, gender, BDI, LCIG treatment duration, disease duration, dyskinesia duration and 
disability, the use of enteral feeding and the occurrence of device related complications at the 
univariate analysis. Significant variables have been reported for the results observed at the 
multivariate linear regression analysis. R
2
 of the model was 0,5 and 0,865 for WL percentage 
and MNA score, respectively.  
 
 
 
